{"filing":{"accession_number":"0001654954-26-006168","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-06-24","report_date":null,"primary_document":"a6263j.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006168/a6263j.htm"},"events":[{"id":13429,"run_id":11927,"accession_number":"0001654954-26-006168","anchor_item_number":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"GSK announces commencement of a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share pursuant to an Agreement and Plan of Merger dated June 9, 2026. This is a material acquisition transaction involving a direct wholly-owned subsidiary of GSK acquiring a NASDAQ-listed biopharmaceutical company, with the Nuvalent Board recommending stockholder acceptance of the offer.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-06-24","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":10566,"accession_number":"0001654954-26-006168","item_number":null,"item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"GSK announces commencement of a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share pursuant to an Agreement and Plan of Merger dated June 9, 2026. This is a material acquisition transaction involving a direct wholly-owned subsidiary of GSK acquiring a NASDAQ-listed biopharmaceutical company, with the Nuvalent Board recommending stockholder acceptance of the offer.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-24T14:40:36.940522+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-06-24"}]}